Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 5/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928745 | 0.90 | SMN1; SMN2 (0.47) | AGTR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22001576 | 0.81 | AGTR2 (0.47) | AGTR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15409979 | 0.76 | HTR2C (0.51) | AGTR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL286830 | 0.76 | HTR2C (0.51) | AGTR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22001466 | 0.76 | ALDH1A1 (0.36) | CYP2C19 | |
| SCHEMBL928026 | 0.76 | SMN1; SMN2 (0.46) | AGTR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14218351 | 0.75 | HTR2C (0.47) | AGTR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7405709 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL34474262 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL22778699 | 0.75 | AGTR2 (0.50) | AGTR2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| EP-3638676-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018228909-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BET1, HRH1, GRIN1 | AGTR2 2102/4885PSEN1 94/4885PSEN2 640/4885 |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | GRIN1, BET1, HRH1 | AGTR2 1892/4885PSEN1 84/4885PSEN2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.